KTC-17798-24349
2 vaccinations
3 coded responses
7 check-ins
3 free-text entries
3 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 337 / FL
- Registered
- 2022-01-13
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-06-14
Dose 1 — Pfizer-BioNTech
-
2021-12-18
Dose 2 — Pfizer-BioNTech
-
2022-01-13
Registered in v-safe
-
2022-01-13
Survey response — day 21, dose 2MedDRA: Hypoaesthesia, Muscle twitching, Pain in extremity, Paraesthesia — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitFree text: Tingling, twitching and numbness in feet, legs, hands and arms. Pain in hands, also.MedDRA releases: 2024-11 · check-in free text available
-
2022-01-13
Report sent to call center — day 21, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · Outpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-01-15
- 2022-01-17
-
2022-01-17
Call successfulCompleted over the phone
- 2022-01-23
- 2022-01-31
-
2022-03-21
Survey response — 3 months, dose 2MedDRA: Migraine — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Worsened migrainesMedDRA releases: 2024-11 · check-in free text available
-
2022-03-21
Report sent to call center — 3 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
-
2022-03-23
Call successfulReported to VAERS during previous contact from GDIT
-
2022-06-18
Survey response — 6 months, dose 2MedDRA: Neuropathy peripheral — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visitFree text: Worsening neuropathyMedDRA releases: 2024-11 · check-in free text available
-
2022-06-18
Report sent to call center — 6 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · Emergency room or emergency department visit · 1 call case(s)
- 2022-06-21
- 2022-12-20
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-06-14 | Pfizer-BioNTech | No |
| 2 | 2021-12-18 | Pfizer-BioNTech | No |
Call center
3 call center cases
2 successful · 1 unsuccessful
VAERS report filed, before or during a call: 2
Free text
Release 10 — day 21, dose 2
Symptoms: Tingling, twitching and numbness in feet, legs, hands and arms. Pain in hands, also.
Release 11 — 3 months, dose 2
Symptoms: Worsened migraines
Release 12 — 6 months, dose 2
Symptoms: Worsening neuropathy
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Hypoaesthesia | · | · | ✓ |
| SD | Migraine | · | · | ✓ |
| SD | Muscle twitching | · | · | ✓ |
| SD | Neuropathy peripheral | · | · | ✓ |
| SD | Pain in extremity | · | · | ✓ |
| SD | Paraesthesia | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release